Clinical Trial Data Often Not Reported in Timely Manner

This article originally appeared here.
Share this content:
Clinical Trial Data Often Not Reported in Timely Manner
Clinical Trial Data Often Not Reported in Timely Manner

(HealthDay News) -- Researchers are not promptly reporting the results of clinical trials to ClinicalTrials.gov, according to an article published in the March 12 issue of the New England Journal of Medicine.

Monique Anderson, M.D., a cardiologist at the Duke University School of Medicine in Durham, N.C., and colleagues conducted an analysis of 13,327 clinical trials that were considered highly likely to be subject to the U.S. Food and Drug Administration Amendments Act provisions. Among the trials in the analysis, 84.8 percent were designed to investigate a new treatment, and two-thirds (65.6 percent) of the trials were funded by private industry.

The one-year reporting rate for industry-sponsored trials was 17 percent, the findings showed. Within five years, results had been posted for 41.5 percent of industry-funded trials. By comparison, the one-year reporting rate was 8.1 percent for clinical trials funded by the U.S. National Institutes of Health (NIH), and 5.7 percent for trials funded by academic institutions or other government agencies. At five years, 38.9 percent of NIH-funded trials and 27.7 percent of academic/non-NIH-funded trials had reported results.

The reporting requirements for ClinicalTrials.gov do allow researchers to delay submitting their data if they want to market a new drug or device and are awaiting approval from the U.S. Food and Drug Administration, Anderson told HealthDay. Taking that into account, the researchers found that about 80 percent of industry-funded trials either met the reporting requirements or had a legally acceptable reason for delay. "We found that industry is really legally doing their job," Anderson said. But NIH-funded and academic trials continued to lag, even with this caveat. Only half of the NIH-funded trials and 45 percent of academic trials either met requirements or had a legally acceptable reason for delay, the researchers found.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »